Wall Street Zen Upgrades Verrica Pharmaceuticals (NASDAQ:VRCA) to "Sell"

Verrica Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen upgraded Verrica Pharmaceuticals from “strong sell” to “sell,” while analyst consensus remains “Hold” with a $12.67 price target.
  • For the latest quarter, Verrica reported a loss of $0.58 per share, missing estimates of a $0.50 loss, while revenue of $6.91 million exceeded expectations of $6.20 million.
  • Shares opened at $2.74, near the stock’s 12-month low of $2.73; the company had a market capitalization of about $47 million.
  • MarketBeat previews top five stocks to own in December.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) was upgraded by Wall Street Zen from a "strong sell" rating to a "sell" rating in a report released on Saturday, Wall Street Zen reports.

Other research analysts also recently issued reports about the stock. Weiss Ratings restated a "sell (e+)" rating on shares of Verrica Pharmaceuticals in a research report on Tuesday, October 13th. Lake Street Capital began coverage on shares of Verrica Pharmaceuticals in a research report on Thursday, August 27th. They set a "buy" rating and a $9.00 price objective for the company. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $12.67.

Read Our Latest Report on VRCA

Verrica Pharmaceuticals Stock Performance

Shares of VRCA opened at $2.74 on Friday. The business's fifty day moving average price is $3.85 and its 200 day moving average price is $5.31. Verrica Pharmaceuticals has a 12-month low of $2.73 and a 12-month high of $9.82. The stock has a market capitalization of $47.07 million, a PE ratio of -1.23 and a beta of 1.69. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.66 and a quick ratio of 1.33.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.08). Verrica Pharmaceuticals had a negative net margin of 189.23% and a negative return on equity of 423.63%. The business had revenue of $6.91 million for the quarter, compared to the consensus estimate of $6.20 million. Equities research analysts forecast that Verrica Pharmaceuticals will post -2.25 EPS for the current year.

Institutional Trading of Verrica Pharmaceuticals

A hedge fund recently raised its stake in Verrica Pharmaceuticals stock. Fifth Third Bancorp increased its stake in shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Free Report) by 100.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,000 shares of the company's stock after buying an additional 14,000 shares during the quarter. Fifth Third Bancorp owned about 0.16% of Verrica Pharmaceuticals worth $134,000 at the end of the most recent quarter. Institutional investors and hedge funds own 42.45% of the company's stock.

Verrica Pharmaceuticals Company Profile

(Get Free Report)

Verrica Pharmaceuticals is a dermatology-focused biopharmaceutical company that develops and commercializes treatments for skin diseases. The company is based in West Chester, Pennsylvania, and its activities include both marketed products and investigational therapies. Its FDA-approved product, YCANTH, is a topical cantharidin treatment for molluscum contagiosum in adults and children ages 2 and older. The treatment is applied by a healthcare professional. Verrica is also developing therapies for other skin conditions.

Further Reading

Analyst Recommendations for Verrica Pharmaceuticals (NASDAQ:VRCA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Verrica Pharmaceuticals Right Now?

Before you consider Verrica Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verrica Pharmaceuticals wasn't on the list.

While Verrica Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines